SG11202010034WA - TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY - Google Patents
TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODYInfo
- Publication number
- SG11202010034WA SG11202010034WA SG11202010034WA SG11202010034WA SG11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA
- Authority
- SG
- Singapore
- Prior art keywords
- osmrß
- disorders
- antibody
- delivery
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662607P | 2018-04-25 | 2018-04-25 | |
US201862718324P | 2018-08-13 | 2018-08-13 | |
US201862765033P | 2018-08-16 | 2018-08-16 | |
US201862731618P | 2018-09-14 | 2018-09-14 | |
US201862757047P | 2018-11-07 | 2018-11-07 | |
US201862775350P | 2018-12-04 | 2018-12-04 | |
US201962789434P | 2019-01-07 | 2019-01-07 | |
US201962794356P | 2019-01-18 | 2019-01-18 | |
PCT/IB2019/000619 WO2019229525A2 (en) | 2018-04-25 | 2019-04-25 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010034WA true SG11202010034WA (en) | 2020-11-27 |
Family
ID=68234020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010034WA SG11202010034WA (en) | 2018-04-25 | 2019-04-25 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY |
Country Status (11)
Country | Link |
---|---|
US (2) | US20210054085A1 (en) |
EP (1) | EP3784347A2 (en) |
JP (1) | JP2021522241A (en) |
KR (1) | KR20210018808A (en) |
CN (1) | CN112533675A (en) |
AU (1) | AU2019276779A1 (en) |
BR (1) | BR112020021739A2 (en) |
CA (1) | CA3096582A1 (en) |
MX (1) | MX2020011172A (en) |
SG (1) | SG11202010034WA (en) |
WO (1) | WO2019229525A2 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012202218B2 (en) * | 2005-02-14 | 2014-05-22 | National Jewish Medical And Research Center | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
WO2006088956A2 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
US9475876B2 (en) * | 2012-05-11 | 2016-10-25 | Wakayama Medical University | Anti oncostatin M receptor beta antibody used for treating atopic dermatitis |
MX351127B (en) * | 2013-05-30 | 2017-10-03 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins. |
TWI755763B (en) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
AU2016210996B2 (en) * | 2015-01-29 | 2021-08-12 | Oxford University Innovation Limited | Therapeutic target and biomarker in IBD |
KR102514173B1 (en) * | 2015-04-14 | 2023-03-27 | 추가이 세이야쿠 가부시키가이샤 | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
-
2019
- 2019-04-25 KR KR1020207033800A patent/KR20210018808A/en unknown
- 2019-04-25 MX MX2020011172A patent/MX2020011172A/en unknown
- 2019-04-25 CA CA3096582A patent/CA3096582A1/en active Pending
- 2019-04-25 AU AU2019276779A patent/AU2019276779A1/en active Pending
- 2019-04-25 EP EP19786854.0A patent/EP3784347A2/en active Pending
- 2019-04-25 CN CN201980039355.2A patent/CN112533675A/en active Pending
- 2019-04-25 BR BR112020021739-5A patent/BR112020021739A2/en unknown
- 2019-04-25 SG SG11202010034WA patent/SG11202010034WA/en unknown
- 2019-04-25 JP JP2020559390A patent/JP2021522241A/en active Pending
- 2019-04-25 US US17/050,261 patent/US20210054085A1/en not_active Abandoned
- 2019-04-25 WO PCT/IB2019/000619 patent/WO2019229525A2/en unknown
-
2023
- 2023-03-30 US US18/193,393 patent/US20240101690A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3784347A2 (en) | 2021-03-03 |
AU2019276779A1 (en) | 2020-12-10 |
JP2021522241A (en) | 2021-08-30 |
WO2019229525A3 (en) | 2020-03-19 |
US20210054085A1 (en) | 2021-02-25 |
MX2020011172A (en) | 2021-01-29 |
US20240101690A1 (en) | 2024-03-28 |
CA3096582A1 (en) | 2019-12-05 |
CN112533675A (en) | 2021-03-19 |
BR112020021739A2 (en) | 2021-01-26 |
WO2019229525A2 (en) | 2019-12-05 |
KR20210018808A (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3377637T (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
IL276383A (en) | Treatment of ophthalmologic diseases | |
EP3429605A4 (en) | Therapeutic for treatment of diseases including the central nervous system | |
EP4009948A4 (en) | Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL278041A (en) | Buffered formulations of bevacizumab for use of treating diseases | |
ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
SG11202010585WA (en) | New treatment of interstitial lung diseases | |
IL282643A (en) | Combination therapy for treatment of hematological diseases | |
EP3897641C0 (en) | Treatment of movement disorders | |
GB201620611D0 (en) | Treatment of neurological diseases | |
ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
IL282361A (en) | Treatment of neurological diseases | |
SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
GB201909438D0 (en) | Treatment of diseases | |
EP4028057A4 (en) | Treatment of skin blistering diseases using antibodies | |
IL274132A (en) | Treatment of skin disorders | |
GB201811912D0 (en) | Treatment of disease | |
GB201811911D0 (en) | Treatment of disease | |
GB201810974D0 (en) | Treatment of disease |